TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07739966: A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors

Sponsor: Daiichi Sankyo · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$9,071,370

Rescue Site Savings

+$5,969,040

Unlock Full NCT07739966 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07739966 Rescue Dossier →